Hochhaus G - Search Results

1

Pharmacokinetics of the dietary supplement creatine.

Persky AM, Brazeau GA, Hochhaus G. Persky AM, et al. Among authors: hochhaus g. Clin Pharmacokinet. 2003;42(6):557-74. doi: 10.2165/00003088-200342060-00005. Clin Pharmacokinet. 2003. PMID: 12793840 Review.

2

Pharmacokinetic aspects of biotechnology products.

Tang L, Persky AM, Hochhaus G, Meibohm B. Tang L, et al. Among authors: hochhaus g. J Pharm Sci. 2004 Sep;93(9):2184-204. doi: 10.1002/jps.20125. J Pharm Sci. 2004. PMID: 15295780 Review.

3

Predicting Pulmonary Pharmacokinetics from In Vitro Properties of Dry Powder Inhalers.

Bhagwat S, Schilling U, Chen MJ, Wei X, Delvadia R, Absar M, Saluja B, Hochhaus G. Bhagwat S, et al. Among authors: hochhaus g. Pharm Res. 2017 Dec;34(12):2541-2556. doi: 10.1007/s11095-017-2235-y. Epub 2017 Aug 10. Pharm Res. 2017. PMID: 28799097

4

Pharmacokinetic/pharmacodynamic profile of mometasone furoate nasal spray: potential effects on clinical safety and efficacy.

Hochhaus G. Hochhaus G. Clin Ther. 2008 Jan;30(1):1-13. doi: 10.1016/j.clinthera.2008.01.005. Clin Ther. 2008. PMID: 18343239 Review.

5

Validation of a simple liquid chromatography assay for creatine suitable for pharmacokinetic applications, determination of plasma protein binding and verification of percent labeled claim of various creatine products.

Persky AM, Hochhaus G, Brazeau GA. Persky AM, et al. Among authors: hochhaus g. J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Aug 25;794(1):157-65. doi: 10.1016/s1570-0232(03)00452-5. J Chromatogr B Analyt Technol Biomed Life Sci. 2003. PMID: 12888208

6

Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate.

Tayab ZR, Fardon TC, Lee DK, Haggart K, McFarlane LC, Lipworth BJ, Hochhaus G. Tayab ZR, et al. Among authors: hochhaus g. Br J Clin Pharmacol. 2007 Nov;64(5):698-705. doi: 10.1111/j.1365-2125.2007.02919.x. Epub 2007 May 17. Br J Clin Pharmacol. 2007. PMID: 17509041 Free PMC article.

7

Advances in single-entity inhaled corticosteroid therapy.

Tayab ZR, Hochhaus G. Tayab ZR, et al. Among authors: hochhaus g. Allergy Asthma Proc. 2007 Mar-Apr;28(2):125-35. doi: 10.2500/aap.2007.28.2981. Allergy Asthma Proc. 2007. PMID: 17479595 Review.

8

Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids.

Hübner M, Hochhaus G, Derendorf H. Hübner M, et al. Among authors: hochhaus g. Immunol Allergy Clin North Am. 2005 Aug;25(3):469-88. doi: 10.1016/j.iac.2005.05.004. Immunol Allergy Clin North Am. 2005. PMID: 16054538 Review.

9

Single- and multiple-dose pharmacokinetics of oral creatine.

Persky AM, Müller M, Derendorf H, Grant M, Brazeau GA, Hochhaus G. Persky AM, et al. Among authors: hochhaus g. J Clin Pharmacol. 2003 Jan;43(1):29-37. doi: 10.1177/0091270002239703. J Clin Pharmacol. 2003. PMID: 12520625 Clinical Trial.

10

A new solution-based intranasal triamcinolone acetonide formulation in patients with perennial allergic rhinitis: how does the pharmacokinetic/pharmacodynamic profile for cortisol suppression compare with an aqueous suspension-based formulation?

Hochhaus G, González MA, Dockhorn RJ, Shilstone J, Karafilidis J. Hochhaus G, et al. J Clin Pharmacol. 2002 Jun;42(6):662-9. doi: 10.1177/00970002042006009. J Clin Pharmacol. 2002. PMID: 12043955 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results